《诺华公司Novartis（NVS）2025年第一季度业绩报告「NYSE」（英文版）（7页）.pdf》由会员分享，可在线阅读，更多相关《诺华公司Novartis（NVS）2025年第一季度业绩报告「NYSE」（英文版）（7页）.pdf（7页珍藏版）》请在三个皮匠报告上搜索。

1、1.Constant currencies(cc),core results and free cash flow are non-IFRS measures.An explanation of non-IFRS measures can be found on page 31 of the Condensed Interim Financial Report.Unless otherwise noted,all growth rates in this Release refer to same period in prior year.2.Please see detailed guida

2、nce assumptions on page 5.Novartis International AG CH-4002 Basel Switzerland https:/ http:/ FINANCIAL RESULTS|FINANZERGEBNISSE Novartis continues strong momentum with double-digit sales growth,robust margin expansion and multiple approvals in Q1 Ad hoc announcement pursuant to Art.53 LR Net sales g

3、rew+15%(cc1,+12%USD)with core operating income1 up+27%(cc,+23%USD)o Sales growth driven by continued strong performance from Entresto(+22%cc),Kisqali(+56%cc),Kesimpta(+43%cc),Cosentyx(+18%cc),Leqvio(+72%cc)and Scemblix(+76%cc)o Core operating income margin1 reached 42.1%,+400 basis points(cc),mainly

4、 driven by higher net sales Operating income grew+44%(cc,+38%USD);net income up+37%(cc,+34%USD)Core EPS1 grew+31%(cc,+27%USD)to USD 2.28 Free cash flow1 of USD 3.4 billion(+66%USD)driven by higher net cash flows from operating activities Selected innovation milestones:o Pluvicto FDA approval for pre

5、-taxane mCRPC o Vanrafia(atrasentan)FDA accelerated approval for IgA nephropathy o Fabhalta(iptacopan)FDA,EC and China NMPA approvals for C3G o Remibrutinib global submissions for CSU,with priority review voucher in US o OAV101 IT Phase III STEER study positive readout in SMA Full-year 2025 guidance

6、2 raised:Sales expected to grow high single digit,core operating income expected to grow low double-digit Basel,April 29,2025 Commenting on Q1 2025 results,Vas Narasimhan,CEO of Novartis,said:“Novartis has had a strong start to the year,delivering a+15%cc increase in sales and a+27%cc rise in core o